Commercial FITs can match NG-MSDT diagnostic results for CRC by lowering the positivity threshold, enhancing sensitivity while maintaining specificity. FITs are accessible, noninvasive CRC screening ...
Sensitivity varied from 10.1 to 36.7%, and specificity varied from 85.5 to 96.6% for advanced colorectal neoplasia. HealthDay News — Fecal immunochemical tests (FITs) have variable sensitivity and ...
VANCOUVER, British Columbia -- The novel multitarget stool RNA test (ColoSense) showed high sensitivity for detecting colorectal neoplasia among adults ages 45 and older, according to the phase III ...
FIT outperformed cfDNA in detecting advanced precancerous colorectal lesions, showing higher sensitivity and specificity. Blood-based tests offer easier implementation and potentially higher adherence ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results